Tyra Biosciences, Inc. Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

Published: 2025-06-30 14:05:54 ET TYRA

Published on 06/30/2025 at 14:05

Tyra Biosciences, Inc. announced that the first patient has been dosed in the Phase 2 SURF302 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). SURF302 (NCT06995677) is an open-label Phase 2 clinical study evaluating the efficacy and safety of TYRA-300 in participants with FGFR3-altered low-grade, IR NMIBC. TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer andletal dysplasia that has demonstrated interim clinical proof-of-concept results in metastatic urothelial cancer (mUC).

TYRA-300's planned clinical development includes three Phase 2 clinical trials: SURF302 for IR NMIBC, BEACH301 for pediatric achondroplasia and SURF301 for mUC.